Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSCPA.L Regulatory News (SCPA)

  • There is currently no data for SCPA

Acquisition

2 Mar 2015 07:00

RNS Number : 1735G
Scapa Group PLC
02 March 2015
 



 

 

 

 

2 March 2015

 

Scapa Group plc

 

Acquisition of First Water Limited ("First Water" or "the Acquisition") and trading update

 

Scapa Group plc ("Scapa"), a global supplier of bonding materials and solutions, is pleased to announce that it has acquired 100% of the issued share capital of First Water Limited ("First Water") based in Ramsbury, UK. The purchase price is comprised of an initial cash consideration of £11.3m with a further cash consideration of up to £4m payable depending on performance in 2016, 2017 and 2018, for a total consideration of up to £15.3m.

 

As at 31 January 2015, unaudited gross assets acquired were £4.0m. Underlying EBITDA for the 12 months to 31 January 2015 was £0.9m on sales of £5.4m. The Acquisition is expected to be earnings enhancing in its first year.

 

First Water has built a reputation as one of the leading designer-manufacturers of advanced wound dressings and skin adhesives. Its patented adhesive polymers and dressing designs allow it to offer its OEM partners - typically multinational woundcare and consumer wellness companies - unique and compelling products for a wide range of clinical and commercial applications.

 

Background to the Acquisition

Scapa's strategy in healthcare is to become the outsourcing partner of choice to our global healthcare customers by offering turn-key solutions in our chosen market sectors of advanced woundcare, consumer wellness, medical devices and drug delivery. We believe we are well positioned to exploit the current trend in healthcare towards outsourcing while increasing our share of customers' total spend. The addition of First Water's strong patent portfolio and technological knowhow to Scapa's expertise in materials, coating and conversion capabilities significantly enhances the value proposition to our customers. First Water also brings a global customer base to which we can offer our full capabilities, leveraging our global footprint to accelerate First Water's growth.

 

First Water's highly experienced management team will remain within the enlarged Group and will strengthen Scapa's Healthcare management expertise and further facilitate the Group's growth in this sector.

 

Details of the Acquisition agreement

Scapa has acquired 100% of the issued share capital of First Water for an initial cash consideration of £11.3m (subject to adjustment following the production of a completion balance sheet to ensure normalised working capital). 

 

Three further cash payments of up to £4m in aggregate will be payable depending upon the achievement of operating profit targets over the following three financial years. The Acquisition will be funded from existing cash reserves and bank facilities.

 

Benefits of the Acquisition

The Directors believe that the Acquisition brings the following advantages to Scapa:

 

- a strengthened turn-key value proposition

- a broadened healthcare technology portfolio with proprietary and patented products

- enhanced innovation and development capabilities

- adds new global customers and potential markets

- the opportunity to leverage global sales channels providing significant cross-selling opportunities and product development potential

- improved global manufacturing infrastructure

- further acceleration of the growth of the Group's Healthcare business

- the Acquisition is expected to be earnings enhancing in the first full year of acquisition

 

Commenting on the Acquisition, Heejae Chae, Chief Executive of Scapa Group, said:

"The acquisition of First Water further enhances our strategy in healthcare to provide turn-key solutions as a strategic outsourcing partner to our global customers. First Water has a strong track record of delivering proven proprietary innovations and technologies which Scapa can now offer to our customers in consumer wellness and advanced woundcare markets in addition to expanding our offering in the medical device and drug delivery markets. Combining Scapa's strengths in material coating, converting and packaging with First Water's R&D and innovation capabilities will enable us to provide a unique one stop solution to our customers."

 

Commenting on the Acquisition, Justin Barnes and Phil Andrews, Co-owners and Directors of First Water, said:

"Becoming part of Scapa's rapidly growing global Healthcare business is a very exciting new chapter in First Water's development. From the outset, it was evident that there is great overlap and opportunity in terms of the enhanced global footprint and technology combinations that the expanded group can access. However, as important to the shareholders and employees of First Water, it was also clear that we share a common culture, a passion for what we do, and considerable care for putting our customers' priorities first. It will remain business as usual but with so much more horizon and opportunity."

 

Scapa Group current trading update

Whilst the year is not yet finished it is anticipated that the Group will have seen good growth over the same period last year, despite currency headwinds. It is anticipated that trading profits will be ahead of market expectations and we look forward to the forthcoming year with confidence. 

 

Scapa Group plc will issue a pre close update on the 9 April 2015.

 

 

 

 

Enquiries:

Scapa Group plc

Heejae Chae - Chief Executive

Paul Edwards - Finance Director

 

 

0161 301 7430

 

Numis Securities Limited

(Nominated Adviser and Joint Broker)

Mark Lander / Richard Thomas

 

 

 

020 7260 1000

 

N+1 Singer (Joint Broker)

Nick Owen

 

 

020 7496 3000

 

Weber Shandwick (Financial PR)

Nick Oborne

 

 

020 7067 0721

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQBCGDXGBGBGUB
Date   Source Headline
12th Jun 20191:16 pmRNSDirector/PDMR Shareholding
12th Jun 20199:16 amRNSHolding(s) in Company
11th Jun 201910:28 amRNSHolding(s) in Company
10th Jun 20192:50 pmRNSAnnual Report and Notice of AGM
10th Jun 201910:05 amRNSHolding(s) in Company
10th Jun 20197:00 amRNSBoard update and additional information
3rd Jun 20194:32 pmRNSHolding(s) in Company
3rd Jun 20197:00 amRNSNotice of Termination of Material Contract
31st May 20199:19 amRNSTotal Voting Rights
28th May 201910:57 amRNSHolding(s) in Company
22nd May 20192:11 pmRNSHolding(s) in Company
21st May 20197:00 amRNSHeejae Chae to step down as Group CEO of Scapa
21st May 20197:00 amRNSScapa Group: Preliminary Results
30th Apr 20199:33 amRNSTotal Voting Rights
26th Apr 20192:21 pmRNSHolding(s) in Company
25th Apr 20192:15 pmRNSHolding(s) in Company
11th Apr 20197:00 amRNSYear-end trading update
29th Mar 20198:50 amRNSTotal Voting Rights
6th Mar 20194:12 pmRNSDirector/PDMR Shareholding
6th Mar 20199:43 amRNSPDMR Notification
28th Feb 20193:23 pmRNSTotal Voting Rights
12th Feb 20194:53 pmRNSDirector/PDMR Shareholding
8th Feb 20194:38 pmRNSDirector/PDMR Shareholding
25th Jan 20198:00 amRNSBlock listing Interim Review
23rd Jan 20197:00 amRNSCapital Markets Day
22nd Jan 20197:00 amRNSDirectorate Change
31st Dec 20189:08 amRNSTotal Voting Rights
21st Dec 201810:16 amRNSDirector/PDMR Shareholding
13th Dec 20184:40 pmRNSDirectorate Change
11th Dec 20182:52 pmRNSDirector/PDMR Shareholding
30th Nov 20189:35 amRNSTotal Voting Rights
23rd Nov 20184:05 pmRNSDirector/PDMR Shareholding
21st Nov 201810:46 amRNSDirector/PDMR Shareholding
20th Nov 20187:00 amRNSHalf-year Report
8th Nov 20184:08 pmRNSHolding(s) in Company
31st Oct 20189:57 amRNSTotal Voting Rights
10th Oct 20187:00 amRNSTrading Statement
2nd Oct 20187:00 amRNSAcquisition
28th Sep 201810:42 amRNSTotal Voting Rights
21st Sep 201812:27 pmRNSDirector/PDMR Shareholding
17th Sep 201810:07 amRNSAnnual Financial Report
13th Sep 20188:21 amRNSAcquisition
31st Aug 20189:53 amRNSTotal Voting Rights
24th Aug 20187:00 amRNSDirectorate Change
7th Aug 201811:59 amRNSBlock listing Interim Review
31st Jul 201810:11 amRNSTotal Voting Rights
26th Jul 20183:26 pmRNSBlock listing Interim Review
17th Jul 20182:46 pmRNSResult of AGM
17th Jul 20187:00 amRNSAGM Statement
10th Jul 20184:08 pmRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.